INTAKE - 538 Annonces

Friday 29 August 2025

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 29 August 2025

Growth hormone-releasing peptides are synthetic, non-natural peptides endowed with potent stimulatory effects on somatotrope secretion in animals and humans. It can promote the secretion of growth hormone, regulate food intake, increase weight, and promote animal growth. GHRP - 6...

Friday 22 August 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...

Wednesday 20 August 2025

Growth hormone-releasing peptides are synthetic, non-natural peptides endowed with potent stimulatory effects on somatotrope secretion in animals and humans. It can promote the secretion of growth hormone, regulate food intake, increase weight, and promote animal growth. GHRP - 6...

Wednesday 20 August 2025

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 20 August 2025

Growth hormone-releasing peptides are synthetic, non-natural peptides endowed with potent stimulatory effects on somatotrope secretion in animals and humans. It can promote the secretion of growth hormone, regulate food intake, increase weight, and promote animal growth. GHRP - 6...

Thursday 14 August 2025

Quantité : 60mg*10via - Prix : USD 650

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 13 August 2025

Quantité : 60mg*10via - Prix : USD 650

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 13 August 2025

Quantité : 50mg*10via - Prix : USD 550

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 13 August 2025

Quantité : 40mg*10via - Prix : USD 450

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 13 August 2025

Quantité : 30mg*10via - Prix : USD 360

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 13 August 2025

Quantité : 20mg*10via - Prix : USD 300

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 13 August 2025

Quantité : 15mg*10via - Prix : USD 230

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 13 August 2025

Quantité : 10mg*10via - Prix : USD 180

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 13 August 2025

Quantité : 5mg*10vial - Prix : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 12 August 2025

Quantité : 15mg*10via - Prix : USD 230

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 12 August 2025

Quantité : 10mg*10via - Prix : USD 180

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 12 August 2025

Quantité : 5mg*10vial - Prix : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Saturday 09 August 2025

Quantité : 15mg*10via - Prix : USD 230

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Saturday 09 August 2025

Quantité : 10mg*10via - Prix : USD 180

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 06 August 2025

Quantité : 1kg; 25kg;

Folic acid can improve megaloblastic anemia, pregnant women intake of safe amount of folic acid can prevent vascular sclerosis, to prevent fetal deformity, preterm delivery; In addition, pregnant women need to be in the first trimester of pregnancy on the start of folic acid supplementation...

Wednesday 06 August 2025

Quantité : 5mg*10vial - Prix : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 05 August 2025

Quantité : 30mg*10via - Prix : USD 360

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 05 August 2025

Quantité : 5mg*10vial - Prix : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 01 August 2025

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 01 August 2025

 Growth hormone-releasing peptides are synthetic, non-natural peptides endowed with potent stimulatory effects on somatotrope secretion in animals and humans. It can promote the secretion of growth hormone, regulate food intake, increase weight, and promote animal growth. GHRP - 6...

Thursday 31 July 2025

Quantité : 20mg*10via - Prix : USD 300

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Thursday 31 July 2025

Quantité : 15mg*10via - Prix : USD 230

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Thursday 31 July 2025

Quantité : 10mg*10via - Prix : USD 180

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...

Thursday 31 July 2025

Quantité : 5mg*10vial - Prix : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).  It is an important tool for obesity research.    It is an antidiabetic agent against type 2 diabetes (T2D)...